Bufexamac

Bufexamac is a selective IIb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with Kds of 0.53 µM and 0.22 µM for HDAC6 and HDAC10. Bufexamac is a nonsteroida anti-inflammatory drug[1][2][3].

Product Specifications

CAS Number

[2438-72-4]

Product Name Alternative

Bufexamic acid

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Aminopeptidase; HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bufexamac.html

Purity

98.0

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

Smiles

O=C(NO)CC1=CC=C(OCCCC)C=C1

Molecular Formula

C12H17NO3

Molecular Weight

223.27

Precautions

H302, H312, H332

References & Citations

[1]Bantscheff M, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29 (3) :255-65.|[2]Oehme I, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A. 2013 Jul 9;110 (28) :E2592-601.|[3]Xiao Q, et al. Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. |[4]Schölz C, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015 Apr;33 (4) :415-23.|[5]Suominen MM, et al. Effects of intra-articular injections of bufexamac suspension in healthy horses. Am J Vet Res. 2001 Oct;62 (10) :1629-35.